A recent study showed long-term use of dupilumab was safe and effective among patients with treatment-resistant atopic dermatitis (AD), and its effectiveness improved over a year.
The prospective, multicenter study included 210 patients with treatment-refractory AD who were treated with dupilumab for 52 weeks and enrolled in the Dutch BioDay registry. Safety and clinical effectiveness of dupilumab were assessed as the main outcomes.
After 16 weeks, the mean percent change in the Eczema Area Severity Index (EASI) was -70.0% (standard deviation [SD], 33.2). This further decreased to -76.6% (SD 30.6) by week 52, the researchers said. They also found 75% improvement on EASI was achieved by 59.9% and 70.3% of patients at weeks 16 and 52, respectively.
In addition, only 17 patients (8.1%) discontinued treatment.
“Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period,” the researchers concluded. They noted that a lack of a control group and the observational design of the study may cause bias.
Ariëns LFM, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol. Published online September 15, 2020. doi:10.1016/j.jaad.2020.08.127